Skip to main content

Peer Review reports

From: Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

Original Submission
26 Jan 2025 Submitted Original manuscript
25 Feb 2025 Reviewed Reviewer Report
25 Feb 2025 Reviewed Reviewer Report - Yifan Li
9 Mar 2025 Reviewed Reviewer Report - Ziyu Li
26 Mar 2025 Author responded Author comments - Yifu He
6 Apr 2025 Reviewed Reviewer Report - Ziyu Li
14 Apr 2025 Author responded Author comments - Yifu He
Resubmission - Version 2
26 Mar 2025 Submitted Manuscript version 2
Publishing
23 Apr 2025 Editorially accepted
9 May 2025 Article published 10.1186/s12885-025-14207-8

You can find further information about peer review here.

Back to article page